NewAmsterdam Pharma Co. N.V. — Form 8-K Summary
Reporting date: September 29, 2026. The filing reports a clinical development event; it does not provide financial statements or period financial results.
Business context and material event
NewAmsterdam announced that the first patient was dosed in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. The announcement is dated September 29, 2026. The press release is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. It contains no comparable-period results or quantified changes.
Outlook, risks, and contingencies
No financial guidance, trial timeline, endpoints, results, or quantified risks are stated in the supplied text. No conclusions about the trial’s outcome can be drawn from first-patient dosing.
Facts for investors to verify
- Review Exhibit 99.1 for additional details on SPINOZA’s design, endpoints, enrollment, and expected timing.
- Check subsequent company disclosures for trial progress, safety information, and results.
- Consult the company’s periodic reports for current financial position, liquidity, and funding needs.